dabigatran etexilate + aspirin + clopidogrel

This is a **combination drug regimen** consisting of three agents: - **Dabigatran etexilate** (an oral direct thrombin inhibitor anticoagulant) - **Aspirin** (an antiplatelet agent that irreversibly inhibits cyclooxygenase-1, suppressing thromboxane A2 and platelet aggregation) - **Clopidogrel** (a P2Y12 receptor antagonist inhibiting ADP-mediated platelet activation and aggregation) The combination is typically used in patients with **atrial fibrillation** (AF) who also have indications for dual antiplatelet therapy, such as after **acute coronary syndrome** (ACS) or **percutaneous coronary intervention** (PCI) with stent placement. It aims to prevent both cardioembolic stroke (via anticoagulation) and stent thrombosis or recurrent coronary events (via antiplatelet effects). Multiple large trials (e.g., RE-LY, RE-DEEM) and observational data show that while dabigatran etexilate maintains efficacy for stroke prevention in patients on antiplatelet therapy, the **bleeding risk increases substantially** when dual antiplatelet agents (aspirin + clopidogrel) are used concurrently with anticoagulation. The risk of major bleeding is approximately doubled for single antiplatelet and more than doubled for dual antiplatelet therapy compared to anticoagulation alone. Therefore, this combination is reserved only for patients with the highest absolute thrombotic risk and for the shortest feasible duration[1][2][3].

Other names

triple antithrombotic therapy with dabigatran, aspirin, and clopidogreldabigatran etexilate with dual antiplatelet therapydabigatran etexilate + DAPT